source
- Novartis shares tumble as three late-stage drug candidates fail trialsNovartis' stock fell more than 13% this week after news that three of its late-stage programs did not meet expectations, pulling down other pharma stocks in the market. The antibody‑oligonucleotid…
- New FDA Oncology Center chief Angelo de Claro pledges AI integration and trial expansionAngelo de Claro, M.D., has taken over as the permanent head of the FDA’s Oncology Center of Excellence after serving as acting director since late 2025. In his first interview, he said the agency w…